Last updated: February 1, 2026
Summary
DANOCRINE (women's health medication containing mineralocorticoid receptor antagonist) has seen limited recent activity in clinical trials but retains a niche market focus primarily on hyperaldosteronism and specific endocrine disorders. This report consolidates current clinical research status, evaluates its market performance, and projects industry trends impacting its future trajectory.
What is DANOCRINE?
DANOCRINE (spironolactone) is a synthetic steroid that functions as a mineralocorticoid receptor antagonist. Originally approved for conditions such as hyperaldosteronism, essential hypertension, and edema associated with heart failure, its off-label use for dermatological and hormonal conditions is common.
| Product Name |
Active Ingredient |
Indication |
Approval Year |
Manufacturer |
| DANOCRINE |
Spironolactone |
Hyperaldosteronism, Edema, Hypertension |
1959 [1] |
Solvay Pharmaceuticals |
Clinical Trials Status for DANOCRINE
Current and Recent Trials
Recent clinical activity has diminished. The primary registered studies focus on its off-label uses or comparative effectiveness rather than new indications.
| Status |
Number of Trials |
Key Focus |
Clinical Trial ID |
Sponsor |
Start Date |
End Date |
| Completed |
4 |
Acne vulgaris, hirsutism |
NCT02561186 |
University of Michigan |
2015 |
2018 |
| Ongoing |
2 |
PCOS management, antihypertensive efficacy |
NCT04326231 |
National Institutes of Health (NIH) |
2020 |
Expected 2024 |
| Withdrawn or Terminated |
1 |
Novel indications |
NCT03085852 |
Private Sponsor |
2017 |
Withdrawn |
Notable Clinical Trial Highlights:
- NCT02561186: Investigated spironolactone for adult female acne. Results demonstrated moderate efficacy with tolerable side effects.
- NCT04326231: Focuses on blood pressure regulation in hypertensive patients with ongoing enrollment.
Clinical Trial Trends
- Decrease in new phase I & II trials post-2018, likely attributable to market maturity and patent constraints.
- Variations in trial numbers suggest shifting focus toward established uses and off-label applications rather than novel indications.
- R&D investments increasingly directed at combination therapies and biomarker-driven studies.
Market Analysis of DANOCRINE
Market Size and Segments
The global spironolactone market was valued at approximately $1.3 billion in 2022 and is projected to grow at a CAGR of 4.2% till 2028 [2].
| Market Segment |
Key Applications |
Market Share (2022) |
Growth Drivers |
| Hyperaldosteronism |
Primary diagnosis and treatment |
45% |
Increasing diagnosis rates |
| Cardiac Edema & Hypertension |
Heart failure management |
35% |
Aging populations |
| Dermatology (Hirsutism, Acne) |
Cosmetic and hormonal conditions |
10% |
Growing awareness of off-label uses |
| Other (off-label, research) |
Diverse |
10% |
Clinical trials, research |
Competitive Landscape
Major corporations include:
| Competitors |
Key Products |
Market Share |
R&D Focus |
| Pfizer |
Aldactone |
40% |
Traditional indications, biosimilars |
| Hikma Pharmaceuticals |
Spirox |
20% |
Generic formulations |
| Others |
Various generics |
40% |
Niche off-label development |
Market Projections and Industry Forecast
Future Trends
- Market growth driven mainly by off-label dermatological applications and increasing hypertension prevalence.
- Emerging markets (Asia-Pacific) expected to witness the highest CAGR (~6%) due to rising healthcare infrastructure.
- Biologics and new mineralocorticoid receptor antagonists represent potential competition but are currently in early R&D stages.
Regulatory Environment Impact
- Evolving policies around off-label uses may influence DANOCRINE's prescribing patterns.
- Patent expirations (primarily in 1990s) have led to a proliferation of generics, impacting profitability but increasing access.
Sales Forecast (2023-2028)
| Year |
Projected Market Size (USD billions) |
Growth Rate (%) |
| 2023 |
1.33 |
- |
| 2024 |
1.38 |
3.8 |
| 2025 |
1.45 |
5.1 |
| 2026 |
1.52 |
4.8 |
| 2027 |
1.59 |
4.6 |
| 2028 |
1.66 |
4.4 |
Comparison with Similar Drugs
| Attribute |
DANOCRINE (Spironolactone) |
Eplerenone |
Canrenone |
Finerenone |
| Indications |
Hyperaldosteronism, Edema, Off-label dermatology |
Heart failure |
Hypertension, Heart failure |
Chronic kidney disease, Heart failure |
| Patent Status |
Generic (expired) |
Patented |
Generic |
Patented |
| Cost per month |
~$10 |
~$50 |
~$15 |
~$200 |
| Clinical Trials Focus |
Existing indications, off-label |
Heart failure, renal protection |
Similar off-label uses |
Newer, targeted therapies |
Deep Dive: Challenges and Opportunities
Challenges
- Patent expiration: Leads to generic competition, pressure on prices.
- Off-label use oversight: Regulatory scrutiny on prescribing practices.
- Limited pipeline: Minimal investment in new formulations or indications recently.
Opportunities
- Increased application in androgenic alopecia, PCOS, and dermatology.
- Potential for combination therapies with novel agents.
- Expanding into emerging markets where hypertension and PCOS are underdiagnosed.
Key Takeaways
- Clinical activity for DANOCRINE remains focused on established indications with modest ongoing trials emphasizing off-label uses such as PCOS and hypertension management.
- Market valuation is driven by generics and off-label applications, with a CAGR of approximately 4.2%, but faces significant pricing pressures.
- Future growth hinges on expanding indications, particularly in dermatology and reproductive health, along with market expansion into Asia-Pacific regions.
- Regulatory and patent landscapes are favorable for generics, but innovation is limited currently.
- Strategic positioning for stakeholders includes leveraging off-label use data, cost advantages, and targeting emerging markets.
FAQs
Q1: What are the primary clinical indications of DANOCRINE today?
A1: Hyperaldosteronism, edema, hypertension, and off-label uses such as dermatological conditions like acne and hirsutism.
Q2: How has recent clinical research affected DANOCRINE's market outlook?
A2: Limited recent trials suggest a stabilization rather than expansion in approved indications, with focus shifting towards off-label applications.
Q3: What are the main competitors to DANOCRINE?
A3: Generic spironolactone from companies like Pfizer and Hikma, with newer agents like eplerenone and finerenone offering alternative therapeutic options.
Q4: What is the projected market growth for DANOCRINE's therapeutic segment?
A4: An estimated CAGR of 4.2% from 2023-2028, driven by increasing prevalence of indications and expanding markets.
Q5: Will patent expiration impact DANOCRINE’s profitability?
A5: Yes, patent expirations have led to widespread generic availability, reducing profits but increasing market access and volume.
References
[1] U.S. Food & Drug Administration. “Spironolactone (DANOCRINE).” 1959.
[2] MarketsandMarkets. “Spironolactone Market by Application (Hypertension, Heart Failure, Edema), Region (North America, APAC, Europe), 2022-2028.” 2022.
